PTH-002 Survival after upper gi stent insertion: a retrospective audit from a single centre

Author(s):  
H Smart ◽  
C Cooper ◽  
C Carr ◽  
N Haslam ◽  
P O’Toole ◽  
...  
2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Iain Blake ◽  
Stuart Chapman ◽  
Paul Turner

Abstract Aims Anastomotic leak and chylothorax are serious complications of cardio-oesophagectomy. The application of a tissue sealant to the anastomosis and ligated thoracic duct could be beneficial in protecting against leaks. We aimed to determine if using Tisseel, a fibrin-based tissue sealant, had any impact on anastomotic or chyle leak rates following cardio-oesophagectomy. Methods All elective cardio-oesophagectomys performed in a tertiary upper GI centre between 01/01/2013 and 01/01/2018 were identified. Patient records were retrospectively analysed to assess basic demographics; whether Tisseel was used; whether anastomotic or chyle leak occurred and if so whether this was managed conservatively or surgically. Results 245 records were available, Tisseel was used in 151 cases (61.6%). Patient demographics were similar between the Tisseel and no Tisseel groups (82.7% vs 77.7% male, mean age 66 vs 65 years). There was no significant difference in anastomotic leak (4.0% vs 7.4%, p = 0.24) or chyle leak (6.6% vs 4.3%, p = 0.44) rates. For patients who had an anastomotic leak there was a significantly lower rate of re-thoracotomy when Tisseel was used (16.7% vs 85.7%, p = 0.021). There was no significant difference in re-thoracotomy rates for chyle leak (40% vs 100%, p = 0.085). Conclusion Our data does not show any significant difference in leak rates when Tisseel is used. However, it does show that Tisseel use is associated with lower rate of re-thoracotomy in patients with anastomotic leak. This could possibly be due to smaller contained leaks. Further work is needed to determine the true benefit of Tisseel use in cardio-oesophagectomy.


2020 ◽  
Vol 4 ◽  
pp. AB169-AB169
Author(s):  
Natasha Khullar ◽  
Thomas Hefferon ◽  
Rena Al-Zubaidy ◽  
Frederik Pretorius

2021 ◽  
Vol 108 (Supplement_9) ◽  
Author(s):  
Martin Michel ◽  
Helen Fifer ◽  
Emily Moran ◽  
Felix Hammett ◽  
Clare Bonner ◽  
...  

Abstract Background The road to recovery from the Covid-19 pandemic has started but no-one knows when it will end. 18 months on from the World Health Organisation declaring a global pandemic on the 11th March 2020 this has had a dramatic impact on both acute and elective hospital services. Whilst, quite rightly, the focus has been on prioritising cancer resections during the pandemic, many patients awaiting benign operations are facing lengthy waiting times. The aim of this study was to quantify the impact of the COVID-19 pandemic on benign upper GI surgery at a single centre compared to previous operating activity levels. Methods Retrospective analysis of computerised theatre records for the first 12 months of the pandemic (11th March 2020-11th March 2021) were compared to average historical data (HD) over the last five years (2015-2019) over the same time frame. Benign upper Gi operations included were cholecystectomy, anti-reflux/hiatus hernia repairs, cardiomyotomies and bariatric procedures. Results Conclusions The Covid-19 pandemic has dramatically affected benign upper GI surgery at our unit. Overall total operation numbers were down by 31% when compared to HD (440 vs 641). The largest deficit was in bariatrics where no bariatric surgery was performed during the first 12 months of the pandemic, which has restarted as of July 2021. There was also a 30% reduction in the number of cholecystectomies performed likely due to initial guidance recommending non-operative management at the start of the pandemic. Hiatal work numbers remained consistent. This quantitative study can direct future service delivery and help guide the post-pandemic recovery.


2015 ◽  
Vol 172 (5) ◽  
pp. 1455-1457 ◽  
Author(s):  
S. Ingen-Housz-Oro ◽  
C. Hotz ◽  
L. Valeyrie-Allanore ◽  
E. Sbidian ◽  
F. Hemery ◽  
...  

BJS Open ◽  
2021 ◽  
Vol 5 (Supplement_1) ◽  
Author(s):  
Nicholas Wong

Abstract Introduction COVID19 has stressed and stretched healthcare resources to the limit, thus the rational deployment of any resource should be necessary and of patient benefit. This retrospective audit aims to ascertain if a policy of two valid group and save tests prior to transurethral prostate surgery is necessary and if this resource can be redistributed safely during the ongoing pandemic. Methods A retrospective review of electronic patient records for patients that underwent transurethral prostate surgery from June 2017 to June 2018. During a single admission for surgery it was identified how many pre-operative group and save tests, and if a post-operative blood transfusion patients underwent. Results 146 patients underwent transurethral prostate surgery between June 2017 to June 2018. 97 patients had two valid group and save tests prior to surgery. 49 patients did not have 2 valid group and save tests. 21 patients had expired tests, 20 had only one valid sample, and 8 had no group and save test at all. No patient underwent a blood transfusion during their admission for transurethral prostate surgery. Conclusion This single centre study illustrates pre-operative group and save tests before transurethral prostate surgery are unnecessary as no patient required an associated blood transfusion during admission; and can safely be omitted. The clinical time and resource could be redirected elsewhere for greater patient benefit. £2855.00 of efficiency savings could be made foregoing unneeded group and save tests. A policy omitting pre-operative group and save before transurethral prostate surgery will be implemented under COVID19 pandemic conditions and re-audited in 6 months.


Sign in / Sign up

Export Citation Format

Share Document